Harmony Biosciences Holdings, Inc. Common Stock (HRMY) — Analysis Summary
Harmony Biosciences Holdings, Inc. Common Stock (HRMY) has a market cap of $2.42B with year-over-year revenue growth of +21.5%. Net margin stands at 18.3%. The stock trades at a P/E ratio of 13.3.
Key Takeaways
- Revenue changed +21.5% year-over-year
- Net margin of 18.3%
- P/E ratio of 13.3
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, HRMY posted revenue growth of +21.5% and trades at a P/E of 13.3.
Harmony Biosciences Holdings, Inc. Common Stock (HRMY)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
293
Headquarters
PLYMOUTH MEETING, PA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.